Molecular docking analysis of α-Topoisomerase II with δ-Carboline derivatives as potential anticancer agents

Selvaraj Ayyamperumal1, Dhananjay Dj2, Vyshnavi Tallapaneni1

  • 1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris - 643001,Tamil Nadu, India.

Bioinformation
|August 16, 2021
PubMed

Insights

New anticancer drug candidates targeting alpha-topoisomerase II (α-Topo II) were designed. These novel carboline-succinimide derivatives show promising binding and stable interactions, identifying seven potential inhibitors for cancer therapy.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Alpha-topoisomerase II (α-Topo II) is crucial for DNA topology, highly expressed in proliferating cells, and a target for anticancer drugs.
  • Delta-carboline derivatives are known potent α-Topo II inhibitors with anticancer activity.
  • Fused carboline-succinimide structures offer potential for selective α-Topo II inhibition via ATP-binding pocket interactions.

Purpose of the Study:

  • To design novel carboline derivatives fused with pyrrolidine-2,5-dione as potential α-Topo II inhibitors.
  • To evaluate the drug-likeness, ADMET properties, and toxicity of designed compounds.
  • To assess the binding affinity and stability of designed compounds with α-Topo II.

Main Methods:

  • Design and virtual screening of 300 carboline-succinimide derivatives.
  • Lipinski's Rule of 5, ADMET, and toxicity predictions.
  • Molecular docking and molecular dynamics simulations against α-Topo II (PDB ID: 1ZXM).

Main Results:

  • Seven compounds (AS89, AS104, AS119, AS209, AS239, AS269, AS299) exhibited significant binding activity compared to the co-crystal ligand.
  • Molecular dynamics simulations confirmed stable binding of ligands within the α-Topo II ATP domain.
  • Binding free energy calculations supported the potential of these seven compounds as α-Topo II inhibitors.

Conclusions:

  • The designed carboline-succinimide derivatives show promise as selective α-Topo II inhibitors.
  • These compounds represent potential lead candidates for developing novel anticancer agents.
  • Further investigation is warranted to explore their therapeutic efficacy in cancer treatment.

Related Concept Videos

DNA Topoisomerases02:02

DNA Topoisomerases

Topoisomerases are enzymes that relax overwound DNA molecules during various cell processes, including DNA replication and transcription. These enzymes regulate positive and negative DNA supercoiling without changing the nucleotide sequence. DNA overwinding in a clockwise direction results in positively supercoiled DNA, whereas underwinding in a counterclockwise direction produces negatively supercoiled DNA.
Types and Mechanism of action
Topoisomerases are divided into two main types. ...
33.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.2K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.5K